Muscle-Specific Kinase Autoimmune Myasthenia Gravis: Report of a Pediatric Case and Literature Review

Abstract

Myasthenia gravis (MG) with antibodies to the muscle-specific tyrosine kinase (MuSK-MG) receptor is a rare entity. It represents 5 to 8% of all MG patients. Few pediatric cases were reported. Clinical presentation is often atypical. It is characterized by predominant involvement of cranial, bulbar, and axial muscles and early respiratory crises. Myokymia and fasciculation are suggestive of MuSK-MG. The clinical course of patients with MuSK-MG is worse than other types of MG. Responses to standard therapies are variable. We report clinical, neurophysiological, serological, and outcome profile of a Tunisian child with MuSK-MG.

Keywords

muscle-specific tyrosine kinase - myasthenia gravis - children - myokymia

• References

• 1 Huang YC, Yeh JH, Chiu HC, Chen WH. Clinical characteristics of MuSK antibody-positive myasthenia gravis in Taiwan. J Formos Med Assoc 2008; 107 (07) 572-575
• 2 Evoli A, Alboini PE, Damato V. , et al. Myasthenia gravis with antibodies to MuSK: an update. Ann N Y Acad Sci 2018; 1412 (01) 82-89
• 3 Skjei KL, Lennon VA, Kuntz NL. Muscle specific kinase autoimmune myasthenia gravis in children: a case series. Neuromuscul Disord 2013; 23 (11) 874-882
• 4 Simon NG, Reddel SW, Kiernan MC, Layzer R. Muscle-specific kinase antibodies: a novel cause of peripheral nerve hyperexcitability?. Muscle Nerve 2013; 48 (05) 819-823
• 5 Matthews HJ, Thambundit A, Allen BR. Anti-MuSK-positive myasthenic crisis in a 7-year-old female. Case Rep Emerg Med 2017; 2017: 8762302
• 6 Takahashi Y, Sugiyama M, Ueda Y. , et al. Childhood-onset anti-MuSK antibody positive myasthenia gravis demonstrates a distinct clinical course. Brain Dev 2012; 34 (09) 784-786
• 7 Guptill JT, Sanders DB, Evoli A. Anti-MuSK antibody myasthenia gravis: clinical findings and response to treatment in two large cohorts. Muscle Nerve 2011; 44 (01) 36-40
• 8 Evoli A, Tonali PA, Padua L. , et al. Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis. Brain 2003; 126 (Pt 10): 2304-2311
• 9 Anlar B, Yilmaz V, Saruhan-Direskeneli G. Long remission in muscle-specific kinase antibody-positive juvenile myasthenia. Pediatr Neurol 2009; 40 (06) 455-456
• 10 Caress JB, Hunt CH, Batish SD. Anti-MuSK myasthenia gravis presenting with purely ocular findings. Arch Neurol 2005; 62 (06) 1002-1003
• 11 Saulat B, Maertens P, Hamilton WJ, Bassam BA. Anti-musk antibody after thymectomy in a previously seropositive myasthenic child. Neurology 2007; 69 (08) 803-804
• 12 Govindarajan R, Iyadurai SJ, Connolly A, Zaidman C. Selective response to rituximab in a young child with MuSK-associated myasthenia gravis. Neuromuscul Disord 2015; 25 (08) 651-652
• 13 Tsiamalos P, Kordas G, Kokla A, Poulas K, Tzartos SJ. Epidemiological and immunological profile of muscle-specific kinase myasthenia gravis in Greece. Eur J Neurol 2009; 16 (08) 925-930
• 14 Chiang LM, Darras BT, Kang PB. Juvenile myasthenia gravis. Muscle Nerve 2009; 39 (04) 423-431
• 15 Pasnoor M, Wolfe GI, Nations S. , et al. Clinical findings in MuSK-antibody positive myasthenia gravis: a U.S. experience. Muscle Nerve 2010; 41 (03) 370-374